SARASOTA, Fla., Aug. 16, 2021 /PRNewswire/ -- INVO Bioscience,
Inc. (Nasdaq: INVO), a medical device company focused on creating
alternative treatments for patients diagnosed with infertility and
developers of INVOcell®, the world's only in vivo culture system,
today announced financial and operating results for the second
quarter ended June 30, 2021 and
provides a business update.
Recent Operational Highlights
- Officially opened the first U.S.-based INVO Center, located in
Birmingham, Alabama in partnership
with reproductive specialists Dr. Nicholas
Cataldo, MD, MPH, Dr. Karen R.
Hammond, DNP, CRNP, and Lisa
Ray, MS, ELD. The new Birmingham practice, named "Innovative
Fertility Specialists, an INVO Center" will provide fertility
treatment utilizing the efficient, effective, and affordable
INVOcell option. The practice has begun seeing patients and expects
to perform initial treatment cycles in September 2021.
- Signed a joint venture agreement with Bloom Fertility to open
an INVO Center in Atlanta,
Georgia. Led by reproductive specialist Dr. Sue Ellen Carpenter, M.D., the center is
scheduled to open in September
2021.
- Completed the site build-out and preparing to open the
Company's INVO Center JV in Monterrey,
Mexico, Positib Fertility, with Drs. Francisco Arredondo and Ramiro Ramirez. Expected to open in the October
timeframe.
- Signed a partnership agreement with Lyfe Medical, LLC to
establish and operate a clinic in the San Francisco Bay area to
offer the INVO procedure. Lyfe Medical will own the clinic while
INVO will set-up and manage an embryology center to provide
laboratory services to the clinic and its patients in exchange for
a share of the clinic's revenue.
- Expanded capabilities within the global OB/GYN vertical with
the appointment of Barbara Levy,
M.D., FACOG, FACS as the SVP, global clinical integration. Dr. Levy
is considered one of the most influential reproductive health
clinical executives in the world, recently serving as Vice
President, Health Policy at the American College of Obstetricians
and Gynecologists (ACOG) and chair of the American Medical
Association/Specialty Society Relative Value Scale Update
Committee.
- Appointed Andrea Goren as CFO,
replacing the Company's past utilization of an outside CFO
consulting firm, to lead the Company's finance function and to
support the execution of the Company's strategic business plan,
including the operational launch of the Company's INVO Center joint
ventures.
Financial Highlights
- Revenues were $208,472 for the
quarter ended June 30, 2021, compared
to $246,072 for the quarter ended
June 30, 2020.
- Net loss for the second quarter of 2021 was approximately
$(1.8) million, which included
approximately $(0.7) million of
non-cash charges primarily related to the debt discount
amortization and equity-based compensation.
- Adjusted EBITDA for the second quarter of 2021 was $(1.3) million, which included $93,969 of JV start-up costs, compared to
$(0.8) million in the prior year's
second quarter (see Adjusted EBITDA Table).
- As of June 30, 2021, the Company
had a cash position of approximately $6.6
million.
Management Discussion
"Our team made excellent progress during the second quarter of
2021 toward our key objectives, headlined by last week's official
opening of our first INVO Center practice in Birmingham, Alabama," commented Steve Shum, CEO of INVO Bioscience. "We
feel INVO is now well positioned for success based on the following
core foundational elements developed over the past 2 years:
- Our Team – An experienced internal operating team with key
positions filled, a strong and diverse board of directors, a
scientific advisory board composed of well-known and respected
fertility industry experts, and key outside KOL's/consultants.
- Our Partners – A growing list of quality distributors around
the world, experienced and motivated JV Partners, and a committed
shareholder base.
- Our Technology – We have gained valuable real market usage data
(and hence further validation) along with a clear understanding of
how our technology "fits" in the industry and the key challenges it
helps solve.
We believe there is a substantial underserved patient population
with infertility challenges and a real need to expand access to
treatment. In our opinion, this is a multi-billion-dollar market
expansion opportunity, and INVOcell is well positioned to address
the unmet medical need."
"The new Birmingham practice,
our very first INVO Center, is a major milestone and one of the
most significant in the Company's history to date. The center
is already off to an encouraging start as we have surpassed our
internal expectations for patient appointments and expected
treatment cycles planned for the first month. The vision to drive
accelerated adoption of the INVOcell solution while also increasing
much needed capacity and patient access within the fertility
industry is coming to reality with this first INVO Center, thanks
to the expertise and commitment of our internal team and
partners."
Mike Campbell, COO further added,
"With the blueprints now firmly in place for our INVO Center model,
we are rapidly moving towards the opening of centers in
Atlanta, Monterrey, Mexico and the San Francisco Bay
area. We expect that Atlanta and
Monterrey centers will both be
opened before the end of the year, as site selections are complete,
equipment has been ordered, staffing is ramping up, and marketing
plans are in place. A San Francisco Bay area center should be
opened shortly thereafter and our ongoing discussions with
additional partners remain active. This is an exciting time for
INVO as we have diversified our business model beyond device sales
exclusively through our distributors, to a model where we will
capture a share of the larger revenue generated by the entire INVO
patient solution."
Shum concluded, "Our goal to democratize fertility treatment by
bringing care to the vast underserved patient population around the
world experiencing infertility challenges is advancing. We
believe a key to this effort will also involve leveraging the
OB/GYN community. In July, we appointed Dr. Barbara Levy as our SVP, global clinical
integration. Dr. Levy is considered one of the most influential
fertility and reproductive health clinical executives in the world
and brings a life-long passion to improving women's health
recognizing that a critical component to that is treatment for
infertility. I am excited to have Dr. Levy help lead this OB/GYN
strategy moving forward."
Financial Results
Revenues for the three months ended June
30, 2021 were approximately $0.21
million, compared to approximately $0.25 million for the same three-month period in
2020. The slight change was the result of a decrease in product
sales to Ferring. Ferring's minimum purchase requirements are based
on a calendar year and hence contribute to quarterly fluctuations.
Revenue pertaining to the Company's INVO Centers will begin to be
recognized in the current, third quarter.
Gross margin reported for the three months ended June 30, 2021 was approximately 93% compared to
approximately 91% for the three months ended June 30, 2020.
Selling, general and administrative expenses for the three
months ended June 30, 2021 were
approximately $2.0 million compared
to approximately $1.3 million for the
three months ended June 30, 2020. The
increase was primarily the result of increased personnel, board and
business development consulting expenses, as well as startup costs
related to our INVO Centers. We incurred approximately $0.6 million of non-cash, stock-based
compensation expense in the period compared to $0.3 million for the same period in the prior
year.
We began to fund additional R&D efforts in 2020 as part of
our 5-day label expansion efforts. R&D expenses were
$0.03 million for the three months
ended June 30, 2021, compared to
$0.03 million for the three months
ended June 30, 2020.
Interest expense and financing fees were approximately
$0.09 million for the three months
ended June 30, 2021, compared to
approximately $0.26 million for the
three months ended June 30, 2020.
Net loss for the three months ended June
30, 2021 was approximately $(1.8)
million compared to approximately $(1.3) million for the three months ended
June 30, 2020. The increase in net
loss was due to increased operating expenses.
Adjusted EBITDA (see Adjusted EBITDA Table) for the three months
ended June 30, 2021 was $(1.3) million, compared to adjusted EBITDA of
$(0.8) million for the three months
ended June 30, 2020.
As of June 30, 2021, the Company
had approximately $6.6 million in
cash compared to approximately $8.4
million on March 31, 2021.
Use of Non-GAAP Measure
Adjusted EBITDA is a non-GAAP measure. This measure is not
intended to be a substitute for those financial measures reported
in accordance with GAAP. Adjusted EBITDA has been included because
management believes that, when considered together with the GAAP
figures, it provides meaningful information related to our
operating performance and liquidity and can enhance an overall
understanding of financial results and trends. Adjusted EBITDA may
be calculated by us differently than other companies that disclose
measures with the same or similar terms. See our attached
financials for a reconciliation of this non-GAAP measure to the
nearest GAAP measure.
Conference Call Details
INVO Bioscience has scheduled a conference call for Monday, August 16, 2021, at 4:30 pm ET (1:30 pm
PT) to review these results and recent events. Interested
parties can access the conference call by dialing (833) 756-0861 or
(412) 317-5751 or can listen via a live Internet webcast at
https://www.webcaster4.com/Webcast/Page/2162/42110, which is also
available in the Investor Relations section of the Company's
website at https://www.invobioscience.com/investors/.
A teleconference replay of the call will be available through
August 23, 2021 at (877) 344-7529 or
(412) 317-0088, confirmation #10158496. A webcast replay will be
available in the Investor Relations section of the Company's
website at https://www.invobioscience.com/investors/ for 90
days.
About INVO Bioscience
We are a medical device company focused on creating simplified,
lower-cost treatments for patients diagnosed with infertility. Our
solution, the INVO® Procedure, is a revolutionary in vivo method of
vaginal incubation that offers patients a more natural and intimate
experience. Our lead product, the INVOcell®, is a patented medical
device used in infertility treatment and is considered an Assisted
Reproductive Technology (ART). The INVOcell® is the first
Intravaginal Culture (IVC) system in the world used for the natural
in vivo incubation of eggs and sperm during fertilization and early
embryo development, as an alternative to traditional In Vitro
Fertilization (IVF) and Intrauterine Insemination (IUI). Our
mission is to increase access to care and expand fertility
treatment across the globe with a goal to lower the cost of care
and increase the availability of care. For more information, please
visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to
(and expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
INVO BIOSCIENCE,
INC.
|
CONSOLIDATED
BALANCE SHEETS
|
(UNAUDITED)
|
|
|
|
June 30,
2021
|
|
|
December
31,
2020
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
Cash
|
$
|
6,643,080
|
|
$
|
10,097,760
|
Accounts
receivable
|
|
47,869
|
|
|
21,699
|
Inventory
|
|
250,784
|
|
|
265,372
|
Prepaid expenses and
other current assets
|
|
289,843
|
|
|
157,700
|
Total current
assets
|
|
7,231,576
|
|
|
10,542,531
|
Property and
equipment, net
|
|
127,151
|
|
|
132,206
|
Capitalized patents,
net
|
|
22,155
|
|
|
5,427
|
Lease right of
use
|
|
1,419,925
|
|
|
79,319
|
Trademarks
|
|
107,287
|
|
|
89,536
|
Notes
receivable
|
|
881,827
|
|
|
-
|
Other
assets
|
|
-
|
|
|
240
|
Investment in joint
ventures
|
|
141,267
|
|
|
98,084
|
Total
assets
|
$
|
9,931,188
|
|
$
|
10,947,343
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
Accounts payable and
accrued liabilities, including related parties
|
$
|
306,252
|
|
$
|
328,927
|
Accrued
compensation
|
|
349,658
|
|
|
527,326
|
Deferred revenue,
current portion
|
|
714,286
|
|
|
714,286
|
Lease liability,
current portion
|
|
96,921
|
|
|
22,707
|
Note payable –
Payroll Protection Program
|
|
-
|
|
|
157,620
|
Convertible notes,
net
|
|
249,936
|
|
|
536,063
|
Income taxes
payable
|
|
-
|
|
|
1,062
|
Total current
liabilities
|
|
1,717,053
|
|
|
2,287,991
|
Lease liability,
net of current portion
|
|
1,355,323
|
|
|
58,634
|
Deferred revenue, net
of current portion
|
|
2,500,000
|
|
|
2,857,143
|
Deferred tax
liability
|
|
469
|
|
|
469
|
Total
liabilities
|
|
5,572,845
|
|
|
5,204,237
|
|
|
|
|
|
|
Stockholders' equity
|
|
|
|
|
|
Common Stock, $.0001
par value; 125,000,000 shares authorized; 10,459,035 and
9,639,268
issued and outstanding as of June 30, 2021 and December 31, 2020,
respectively
|
|
1,046
|
|
|
964
|
Additional paid-in
capital
|
|
40,864,011
|
|
|
37,978,224
|
Accumulated
deficit
|
|
(36,506,714)
|
|
|
(32,236,082)
|
Total
stockholders' equity
|
|
4,358,343
|
|
|
5,743,106
|
|
|
|
|
|
|
Total liabilities and
stockholders' equity
|
$
|
9,931,188
|
|
$
|
10,947,343
|
INVO BIOSCIENCE,
INC.
|
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
(UNAUDITED)
|
|
|
|
For the Three
Months Ended
June 30,
|
|
For the Six Months
Ended
June 30,
|
|
|
|
2021
|
|
|
2020
|
|
|
2021
|
|
|
2020
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Product
revenue
|
|
$
|
29,900
|
|
$
|
67,500
|
|
$
|
535,852
|
|
$
|
147,500
|
License
revenue
|
|
|
178,572
|
|
|
178,572
|
|
|
357,143
|
|
|
357,143
|
Total
revenue
|
|
$
|
208,472
|
|
$
|
246,072
|
|
$
|
892,995
|
|
$
|
504,643
|
Cost of goods
sold:
|
|
|
|
|
|
|
|
|
|
|
|
|
Production
costs
|
|
|
12,163
|
|
|
18,739
|
|
|
72,477
|
|
|
46,301
|
Depreciation
|
|
|
2,432
|
|
|
2,431
|
|
|
4,863
|
|
|
4,863
|
Total cost of goods
sold
|
|
|
14,595
|
|
|
21,170
|
|
|
77,340
|
|
|
51,164
|
Gross
profit
|
|
|
193,877
|
|
|
224,902
|
|
|
815,655
|
|
|
453,479
|
Operating
expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and
administrative
|
|
|
2,049,422
|
|
|
1,252,939
|
|
|
4,164,725
|
|
|
2,847,985
|
Research and
development
|
|
|
31,016
|
|
|
34,890
|
|
|
97,283
|
|
|
64,940
|
Total operating
expenses
|
|
|
2,080,438
|
|
|
1,287,829
|
|
|
4,262,008
|
|
|
2,912,925
|
Loss from
operations
|
|
|
(1,886,561)
|
|
|
(1,062,927)
|
|
|
(3,446,353)
|
|
|
(2,459,446)
|
Other income
(expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
income
|
|
|
159,126
|
|
|
-
|
|
|
159,126
|
|
|
-
|
Interest
income
|
|
|
2,425
|
|
|
-
|
|
|
4,438
|
|
|
-
|
Interest
expense
|
|
|
(91,125)
|
|
|
(259,954)
|
|
|
(986,351)
|
|
|
(307,827)
|
Foreign currency
exchange loss
|
|
|
(1,028)
|
|
|
-
|
|
|
(1,492)
|
|
|
-
|
Total other income
(expense )
|
|
|
69,398
|
|
|
(259,954)
|
|
|
(824,279)
|
|
|
(307,827)
|
Loss before income
taxes
|
|
|
(1,817,163)
|
|
|
(1,322,881)
|
|
|
(4,270,632)
|
|
|
(2,767,273)
|
Provision for
income taxes
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
Net loss
|
|
$
|
(1,817,163)
|
|
$
|
(1,322,881)
|
|
$
|
(4,270,632)
|
|
$
|
(2,767,273)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.17)
|
|
$
|
(0.27)
|
|
$
|
(0.42)
|
|
$
|
(0.56)
|
Diluted
|
|
$
|
(0.17)
|
|
$
|
(0.27)
|
|
$
|
(0.42)
|
|
$
|
(0.56)
|
Weighted average
number of
common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
10,444,150
|
|
|
4,932,942
|
|
|
10,167,624
|
|
|
4,925,469
|
Diluted
|
|
|
10,444,150
|
|
|
4,932,942
|
|
|
10,167,624
|
|
|
4,925,469
|
|
Adjusted
EBITDA
|
|
|
|
|
Three Months
Ended
|
|
Six Months
Ended
|
|
|
June 30
|
|
June 30
|
|
|
2021
|
|
2020
|
|
2021
|
|
2020
|
|
|
|
|
|
|
|
|
Net Loss
|
$
(1,817,163)
|
|
$
(1,322,881)
|
|
$
(4,270,632)
|
|
$
(2,767,273)
|
|
Other
Income
|
(159,126)
|
|
-
|
|
(159,126)
|
|
-
|
|
Interest
expense
|
9,707
|
|
(2,991)
|
|
44,778
|
|
44,882
|
|
Foreign currency
exchange loss
|
1,492
|
|
-
|
|
1,492
|
|
-
|
|
Stock-based
compensation
|
235,144
|
|
65,309
|
|
427,208
|
|
406,772
|
|
Stock option
expense
|
384,083
|
|
214,915
|
|
760,606
|
|
596,390
|
|
Amortization of debt
discount
|
76,980
|
|
223,027
|
|
937,135
|
|
262,945
|
|
Depreciation and
amortization
|
(2,695)
|
|
(2,551)
|
|
5,959
|
|
5,958
|
Adjusted
EBITDA*
|
$
(1,271,579)
|
|
$
(825,172)
|
|
$
(2,252,580)
|
|
$
(1,450,326)
|
|
|
|
|
|
|
|
|
|
|
*Adjusted to also
include non-cash, stock-based expensing
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-reports-second-quarter-2021-financial-and-operating-results-and-provides-business-update-301356114.html
SOURCE INVO Bioscience, Inc.